Amylin, Lilly and Alkermes Submit Reply to FDA Complete Response Letter for BYDUREON(TM)

SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., April 22, 2010 - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New [...]

Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations

INDIANAPOLIS, March 17, 2010 - Eli Lilly and Company (NYSE: LLY) today issued a statement and details regarding the stolen company products from its distribution operations in Enfield, Connecticut on Sunday, March 14.
Lilly is working with the U.S. Food and Drug Administration’s Office of Criminal Investigations (FDA), and other law enforcement officials, to recover cases of [...]

Amylin, Lilly and Alkermes Receive Complete Response Letter From FDA for Exenatide Once Weekly Submission

SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., March 15, 2010 - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON(TM) (exenatide for extended-release injectable suspension).
In the [...]